Thanks to the recent discoveries in genetics and signaling pathways in HCL and HCL-like disorders, new targeted therapies have been developed and have proven their efficacy and safety in several clinical trials: BRAFi, MEKi, BTKi and/or anti-CD22 immunotoxins. Here, CD22 is linked to hairy cell leukemia.